190 related articles for article (PubMed ID: 24942334)
121. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
[TBL] [Abstract][Full Text] [Related]
122. Clinicopathological Significance of
Wang J; Shen J; Huang C; Cao M; Shen L
J Cancer; 2019; 10(10):2332-2341. PubMed ID: 31258736
[No Abstract] [Full Text] [Related]
123. Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data.
Kim E; Jung S; Park WS; Lee JH; Shin R; Heo SC; Choe EK; Lee JH; Kim K; Chai YJ
BMC Cancer; 2019 Apr; 19(1):302. PubMed ID: 30943948
[TBL] [Abstract][Full Text] [Related]
124. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
125. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.
Jesinghaus M; Konukiewitz B; Keller G; Kloor M; Steiger K; Reiche M; Penzel R; Endris V; Arsenic R; Hermann G; Stenzinger A; Weichert W; Pfarr N; Klöppel G
Mod Pathol; 2017 Apr; 30(4):610-619. PubMed ID: 28059096
[TBL] [Abstract][Full Text] [Related]
126. Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.
Bruno W; Martinuzzi C; Andreotti V; Pastorino L; Spagnolo F; Dalmasso B; Cabiddu F; Gualco M; Ballestrero A; Bianchi-Scarrà G; Queirolo P; Grillo F; Mastracci L; Ghiorzo P;
Oncotarget; 2017 Jan; 8(5):8069-8082. PubMed ID: 28039443
[TBL] [Abstract][Full Text] [Related]
127. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
128. Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.
Guan Y; Zhang Y; Xiao L; Li J; Wang JP; Chordia MD; Liu ZQ; Chung LW; Yue W; Pan D
Mol Pharm; 2017 Jan; 14(1):1-13. PubMed ID: 26992462
[TBL] [Abstract][Full Text] [Related]
129. Mutanome and expression of immune response genes in microsatellite stable colon cancer.
Sanz-Pamplona R; Gil-Hoyos R; López-Doriga A; Alonso MH; Aussó S; Molleví DG; Santos C; Sanjuán X; Salazar R; Alemany R; Moreno V
Oncotarget; 2016 Apr; 7(14):17711-25. PubMed ID: 26871478
[TBL] [Abstract][Full Text] [Related]
130. Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma.
Condelli V; Maddalena F; Sisinni L; Lettini G; Matassa DS; Piscazzi A; Palladino G; Amoroso MR; Esposito F; Landriscina M
Oncotarget; 2015 Sep; 6(26):22298-309. PubMed ID: 26084290
[TBL] [Abstract][Full Text] [Related]
131. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?
Yokota T
Anticancer Agents Med Chem; 2012 Feb; 12(2):163-71. PubMed ID: 22043994
[TBL] [Abstract][Full Text] [Related]
132. Systematic review of tumour budding and association with common mutations in patients with colorectal cancer.
Hatthakarnkul P; Quinn JA; Matly AAM; Ammar A; van Wyk HC; McMillan DC; Edwards J
Crit Rev Oncol Hematol; 2021 Nov; 167():103490. PubMed ID: 34619332
[TBL] [Abstract][Full Text] [Related]
133. The BRAF mutation is associated with the prognosis in colorectal cancer.
Ahn TS; Jeong D; Son MW; Jung H; Park S; Kim H; Bae SB; Kim HJ; Jeon YW; Lee MS; Baek MJ
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1863-71. PubMed ID: 24942334
[TBL] [Abstract][Full Text] [Related]
134. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
135. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
136. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
[TBL] [Abstract][Full Text] [Related]
137.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
138.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
139.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
140.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
